Grant: Project Grant
University of Manitoba
$1,097,776.00
Validating a Novel Strategy to Prevent Synaptic Dysfunction in Alzheimer's Disease
EF 2025-26
Résumé
It is estimated that approximately 750,000 Canadians are living with Alzheimer's or a related dementia. By 2050, this number is expected to reach 1,700,000. The impact on patients, families and caregivers is made worse by the fact that existing treatments provide at best modest symptomatic relief. The proposed research is focused on validating a novel approach for the development of a disease modifying treatment in AD. Our approach is based on our development of a small peptide-based treatment that is designed to prevent the decline of neuronal communication in Alzheimer's that causes memory loss in patients. The potential to advance patient care and/or patient outcomes by slowing the onset on AD is highlighted by the findings from the Landmark study by the Alzheimer's Society of Canada, which reported that treatments able to delay the onset of dementia by merely 1 year could reduce the number of new cases by close to 30% by 2050.
Programme
Project Grant
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
565504
Name
Jackson Michael F
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Biological and Clinical Aspects of Aging
Projecttitle
Validating a Novel Strategy to Prevent Synaptic Dysfunction in Alzheimer's Disease
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$1,097,776
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Alzheimer'S Disease; Animal Models Of Disease; Cognitive Tests; Electrophysiology; Fluorescence Imaging; Hippocampus; Neuroinflammation; Nmda Receptor Signalling; Pannexins; Synaptotoxicity
Abstract
It is estimated that approximately 750,000 Canadians are living with Alzheimer's or a related dementia. By 2050, this number is expected to reach 1,700,000. The impact on patients, families and caregivers is made worse by the fact that existing treatments provide at best modest symptomatic relief. The proposed research is focused on validating a novel approach for the development of a disease modifying treatment in AD. Our approach is based on our development of a small peptide-based treatment that is designed to prevent the decline of neuronal communication in Alzheimer's that causes memory loss in patients. The potential to advance patient care and/or patient outcomes by slowing the onset on AD is highlighted by the findings from the Landmark study by the Alzheimer's Society of Canada, which reported that treatments able to delay the onset of dementia by merely 1 year could reduce the number of new cases by close to 30% by 2050.
Competitiondate
202603
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Jackson, Michael F
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,097,776~ $0~
